Alembic Pharmaceuticals Limited has informed the Exchange about Transcript
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Alembic Pharmaceuticals reported Q4 FY'26 revenue of INR 1,838 crores (up 4% YoY) with EBITDA before R&D at INR 455 crores, margins at 25%. Full year FY'26 revenue grew 10% with PAT at INR 675 crores (up 16%). Management guided FY'27 for low double-digit revenue growth, R&D spend of INR 750-800 crores, and capex of INR 300-350 crores. The U.S. branded business (Pivya launched Feb 2026) is currently dragging margins by 100-150 bps but expected to turnaround in 1-2 quarters. International generic business targets low to mid-teen growth, API business high single to low double-digit growth, and India business expected to approach market growth. Management aims to return to 20% EBITDA margins over 2-3 years. The company highlighted improved capacity utilization at F2/F3 facilities and ongoing contract manufacturing contributions.
The company is navigating near-term margin pressure from U.S. branded business investments while building execution capabilities. Management's confidence in margin improvement and return to 20% EBITDA target over medium term is positive for long-term shareholders, though near-term profitability remains under pressure from higher R&D and new business build-out costs.